Virax Biolabs Group Ltd

VRAX Nasdaq SEC CIK 1885827
Follow Virax Biolabs Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$8M−$6M−$4M−$2M$0$2MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$6.3K−$6.1M
FY24$156.4K−$6.7M
FY23$8.6K−$5.5M
FY22$0−$1.7M
FY21$123.8K−$651K
FY20--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100000%−75000%−50000%−25000%0%25000%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25−838.2%−97344.8%−95739.2%
FY2432.3%−4153.3%−4304.8%
FY23−15.9%−66963.7%−63748.3%
FY22---
FY21−7.6%−520.5%−525.8%
FY20---
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Virax Biolabs
  • Healthcare median
−100000%−75000%−50000%−25000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearVirax BiolabsHealthcare median
FY25−95739.2%−30.6%
FY24−4304.8%−47%
FY23−63748.3%−58%
FY22-−80.4%
FY21−525.8%−71.9%
FY20-−62.2%